ArticleStem cells translational medicine2026
Intranasal stem cell treatment ameliorates neuroinflammation and myelin aberrations in fetal growth-restricted rat pups.
Article in Stem cells translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Fetal growth restriction (FGR), a condition in which a fetus fails to reach its full growth potential, affects approximately 30 million infants worldwide each year and increases the risk of long-term neurodevelopmental deficits. Currently, no effective therapies exist to mitigate FGR-induced neurological impairments. Mesenchymal stem cells (MSCs) have emerged as a promising neuroregenerative therapeutic approach. Here, we used the reduced uterine perfusion pressure (RUPP) rat model of chronic placental hypoperfusion-induced FGR. We explored, for the first time, intranasal MSC administration in the early postnatal period in growth-restricted offspring as a minimally invasive and clinically feasible cell delivery approach. RUPP pups received human Wharton's jelly-derived MSCs or vehicle intranasally at postnatal day 5 (P5) or P10, and neuropathological outcomes were assessed at P20. Pups from sham-operated dams served as controls. Intranasal MSC treatment, particularly at the early postnatal treatment timepoint (P5), ameliorated key neuropathological outcomes, as evidenced by improved brain weight and cortical myelination, enhanced oligodendrocyte maturation, and dampened microglial activation compared to vehicle-treated RUPP pups. Functional impairments, measured between P13 and P56 by eye opening, grip strength, and foot faults on the tapered beam walk, showed no significant improvement. Our findings provide proof-of-concept that early-life stem cell therapy provides histological improvements in RUPP-induced brain abnormalities. Although further optimization is needed to establish whether these effects translate into functional benefits, intranasal MSCs represent a promising, minimally invasive neuroregenerative strategy with potential clinical relevance for newborns affected by chronic placental insufficiency-induced FGR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.